The incidence of selected oncogenic events in multiple myeloma (MM) tumors and human MM cell lines (HMCL).
| . | MM Tumor . | HMCL . |
|---|---|---|
| *Karyotypic abnormalities of c-myc are 15% in all MM tumors, but the incidence is 47% in 36 advanced MM tumors that generated metaphase chromosomes. | ||
| ≥ 1 IgH translocation | 55%–73% | 92% |
| ≥ 2 IgH independent translocations | < 5 | 50 |
| ≥ 3 IgH independent translocations | < 1 | 13 |
| 5 Recurrent Translocations (combined) | 40% | 89% |
| 11q13 (cyclin D1) | 15 | 29 |
| 6p21 (cyclin D3) | 3 | 3 |
| 4p16.3 (FGFR3 + MMSET) | 15 | 26 |
| 16q23 (c-maf) | 5 | 21 |
| 20q11 (maf b) | 2 | 11 |
| Ectopic cyclin D1 expression [no t(11;14)] | 43 | 0 |
| 8q24 (c-myc) karyotypic abnormality | 15 (47*) | 88 |
| . | MM Tumor . | HMCL . |
|---|---|---|
| *Karyotypic abnormalities of c-myc are 15% in all MM tumors, but the incidence is 47% in 36 advanced MM tumors that generated metaphase chromosomes. | ||
| ≥ 1 IgH translocation | 55%–73% | 92% |
| ≥ 2 IgH independent translocations | < 5 | 50 |
| ≥ 3 IgH independent translocations | < 1 | 13 |
| 5 Recurrent Translocations (combined) | 40% | 89% |
| 11q13 (cyclin D1) | 15 | 29 |
| 6p21 (cyclin D3) | 3 | 3 |
| 4p16.3 (FGFR3 + MMSET) | 15 | 26 |
| 16q23 (c-maf) | 5 | 21 |
| 20q11 (maf b) | 2 | 11 |
| Ectopic cyclin D1 expression [no t(11;14)] | 43 | 0 |
| 8q24 (c-myc) karyotypic abnormality | 15 (47*) | 88 |